Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr 30;36(9):1363-1382.
doi: 10.1002/sim.7225. Epub 2017 Jan 24.

Sizing clinical trials when comparing bivariate time-to-event outcomes

Affiliations

Sizing clinical trials when comparing bivariate time-to-event outcomes

Tomoyuki Sugimoto et al. Stat Med. .

Abstract

Clinical trials with multiple primary time-to-event outcomes are common. Use of multiple endpoints creates challenges in the evaluation of power and the calculation of sample size during trial design particularly for time-to-event outcomes. We present methods for calculating the power and sample size for randomized superiority clinical trials with two correlated time-to-event outcomes. We do this for independent and dependent censoring for three censoring scenarios: (i) the two events are non-fatal; (ii) one event is fatal (semi-competing risk); and (iii) both are fatal (competing risk). We derive the bivariate log-rank test in all three censoring scenarios and investigate the behavior of power and the required sample sizes. Separate evaluations are conducted for two inferential goals, evaluation of whether the test intervention is superior to the control on: (1) all of the endpoints (multiple co-primary) or (2) at least one endpoint (multiple primary). Copyright © 2017 John Wiley & Sons, Ltd.

Keywords: dependent censoring; log-rank test; multiple endpoints; semi-competing risk; time-dependent association.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Behavior of the total sample sizes Nmp as a function of the correlation ρ(j) for ψ2-1=1.3, 1.5 and 1.7, arranged from the left for S2(1)(τ)=0.4, 0.5, 0.6 and from the top following to Nmp(nc) from the both non-fatal case, Nmp(nc) and Nmp(c) of one fatal case and Nmp(c) of both fatal case, given 1 − β = 0.8, α = 0.025, τa = 2, τf = 3, ψ1-1=1.7,S1(1)(τ)=0.3 and early dependency

References

    1. Fine JP, Jiang H, Chappell R. On semi-competing risks data. Biometrika. 2001;88:907–919. doi: 10.1093/biomet/88.4.907. - DOI
    1. Hamasaki T, Sugimoto T, Evans SR, Sozu T. Sample size determination for clinical trials with co-primary outcomes: exponential event times. Pharmaceutical Statistics. 2013;12:28–34. doi: 10.1002/pst.1545. - DOI - PMC - PubMed
    1. Sugimoto T, Sozu T, Hamasaki T, Evans SR. A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints. Biostatistics. 2013;14:409–421. doi: 10.1093/biostatistics/kxs057. - DOI - PMC - PubMed
    1. Offen W, Chuang-Stein C, Dmitrienko A, Littman G, Maca J, Meyerson L, Muirhead R, Stryszak P, Boddy A, Chen K, Copley-Merriman K, Dere W, Givens S, Hall D, Henry D, Jackson JD, Krishen A, Liu T, Ryder S, Sankoh AJ, Wang J, Yeh CH. Multiple co-primary endpoints: medical and statistical solutions. Drug Information Journal. 2007;41:31–46. doi: 10.1177/009286150704100105. - DOI
    1. Hung HMJ, Wang SJ. Some controversial multiple testing problems in regulatory applications. Journal of Biopharmaceutical Statistics. 2009;19:1–11. doi: 10.1080/10543400802541693. - DOI - PubMed

Publication types

LinkOut - more resources